Insider Buying: Cardiol Therapeutics Inc. (TSE:CRDL) Senior Officer Buys 18,900 Shares of Stock

Cardiol Therapeutics Inc. (TSE:CRDL - Get Free Report) Senior Officer Andrew Warwick Hamer acquired 18,900 shares of the stock in a transaction that occurred on Thursday, December 19th. The shares were bought at an average price of C$1.88 per share, with a total value of C$35,606.69.

Cardiol Therapeutics Trading Up 0.6 %

Shares of CRDL traded up C$0.01 during trading hours on Tuesday, hitting C$1.81. 10,756 shares of the stock were exchanged, compared to its average volume of 134,137. Cardiol Therapeutics Inc. has a fifty-two week low of C$1.09 and a fifty-two week high of C$4.26. The company has a debt-to-equity ratio of 1.07, a current ratio of 2.39 and a quick ratio of 6.84. The business has a 50-day moving average of C$2.36 and a 200-day moving average of C$2.68. The firm has a market capitalization of C$126.48 million, a P/E ratio of -4.11 and a beta of 0.70.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.